In a study with 285 patients with JDM (112), anti-MDA5 antibodies were detectable in 7.4% of patients (21/285) and a recent review reports a prevalence of 0–13% in Europe and USA (113). Here, IFIH1 is linked to juvenile dermatomyositis.